Shelter Pharma Ltd
Incorporated in 2007, Shelter Pharma Ltd manufactures pharma products including
food supplements for animals[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Number of Distributors (Stockists) Nos. ・Standalone data |
|
||
| Number of Export Countries count ・Standalone data |
|||
| Number of Product Formulations Nos. ・Standalone data |
|||
| States Covered (Domestic Distribution) count ・Standalone data |
|||
| Total Employees Nos. ・Standalone data |
|||
| Manufacturing Capacity - Tablets (Single Shift, Per Annum) Nos. per annum ・Standalone data |
|||
| Number of Doctors in Network Nos. ・Standalone data |
|||
| Number of Retail Pharmacies Nos. ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment
- Board approved conversion of 4,65,000 warrants into equity shares on 16 October 2026, raising ₹1.47 crore.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, October 16, 2026 For Conversion Of Warrants Into Equity Shares
- Board approved conversion of 4,65,000 warrants into equity shares for Rs. 1.47 crore.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Attached herewith Compliance Certificate forthe quarter ended 30th September, 2026
-
Announcement under Regulation 30 (LODR)-Change in Management
- Ms. Vinita Shivraj Gadhavi regularized as Independent Director for five years from 31 July 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Concalls
-
Jun 2026Transcript PPT
-
May 2026REC
Business Overview:[1]
SPL is a GMP & HACCP certified and ISO 9001:2015 certified manufacturer and seller
of a range of herbal Ayurvedic medicines in
India for humans and food supplements for animals